| Abstrakt: |
Simple Summary: Cancer and stroke are leading causes of global disability and mortality. With improvements in cancer-associated mortality and advancements in treatment of active malignancy, it is more common to encounter patients with ischemic stroke and active malignancy. In this paper, we first review the epidemiology regarding cancer-associated ischemic stroke and management challenges. We then highlight the pathophysiological contributors to the development of hypercoagulability, as well as tumor-associated and treatment-associated contributors to stroke in patients with cancer. The final section addresses acute treatment, secondary prevention, recovery, and future directions regarding management of cancer-associated stroke. Cancer and stroke are leading causes of global disability and mortality. With improvements in cancer-associated mortality and advancements in treatment of active malignancy, it is more common to encounter patients with ischemic stroke and active malignancy. Evidence suggests that cancer-associated ischemic stroke is a unique subtype of stroke; however, there is limited guidance when considering diagnostic workup, secondary prevention, rehabilitation, and future directions within this population. In this narrative review, we aim to describe the epidemiology, pathophysiological mechanisms, management, and future directions regarding understanding of cancer-associated ischemic stroke. [ABSTRACT FROM AUTHOR] |
